Beelitz

Researchers are evaluating the efficacy, safety, and pharmacokinetics of intravenous prasinezumab compared with placebo in people with early-stage Parkinson's disease. Participants must be on stable symptomatic monotherapy with levodopa and meet specific criteria including body weight and disease stage. This Phase III study aims to understand how prasinezumab affects motor progression in Parkinson's disease. Participants will receive either prasinezumab or a placebo through intravenous infusion following a schedule outlined in the study protocol. The study compares these two groups to assess the impact of prasinezumab on disease progression. The treatments are administered regularly over the course of the trial. During the study, participants will be monitored for motor progression using the Movement Disorder Society - Unified Parkinson's Disease Rating Scale Part III score, with assessments continuing up to at least week 104. Researchers will also evaluate safety and pharmacokinetics throughout the trial. Participants are required to adhere to contraception requirements and attend scheduled visits for evaluations and infusions.

Researchers are evaluating the effectiveness of TEV-56286, taken orally, for treating adults with Multiple System Atrophy (MSA), a rare neurological condition. This Phase 2 trial aims primarily to measure changes in patients' symptom severity using the Modified Unified Multiple System Atrophy Rating Scale over 48 weeks. The study also examines other specific effects of TEV-56286 and evaluates its safety and tolerability. Participants will be randomly assigned to receive either TEV-56286 capsules or a matching placebo, both given orally during a 48-week double-blind treatment period. The overall study duration for each participant is about 56 weeks, which includes a screening phase lasting up to 4 weeks and a follow-up visit approximately 4 weeks after treatment ends. The trial is conducted across multiple countries including the US, Israel, Italy, Spain, Germany, France, Japan, and Serbia. During the study, participants will undergo regular assessments to monitor their condition using rating scales specific to MSA symptoms. Researchers will track changes from baseline scores over time to evaluate treatment effects. Safety and tolerability will be closely watched throughout the study and during follow-up visits. The total planned duration of the study is around 27 months.

Researchers are investigating the effect of a vibrating therapy ball called the VILIM ball on hand tremors in patients with Parkinson's disease, essential tremor, and other tremor syndromes. These tremors often do not respond well to medication, leading to invasive treatments like deep brain stimulation. The study aims to evaluate this non-invasive, portable physiotherapy device as a potential complementary treatment to reduce tremor severity and improve daily activities. The study compares the use of the vibrating therapy ball (ball-on) versus a control condition without vibration (ball-off). The VILIM ball is customized to each patient's tremor during a training phase and is designed to reduce tremor temporarily by up to 50%, with effects lasting up to 4 hours. This allows patients to perform everyday tasks such as eating and writing more easily. The evaluation includes physician assessment based on video documentation in a single-blinded manner. Participants will be assessed before and after using the therapy ball, with measurements including Clinical Global Impression Severity scores, disease-specific tremor scales, and tremor analysis data from accelerometers. Functional tasks like bringing a spoon to the mouth and pouring water will be tested. Both doctors and patients will rate improvements. The study monitors safety and therapy effects over a 2-year period to understand how the vibrating ball influences tremor and daily function.

Researchers are studying patients with neurodegenerative diseases such as multiple system atrophy (MSA), Parkinson's disease, progressive supranuclear palsy (PSP), and motor neuron disease to better understand swallowing difficulties and laryngeal function. These disorders often cause neurogenic dysphagia, which can lead to serious complications like dehydration, malnutrition, and pneumonia, affecting patient survival and quality of life. The study aims to systematically record characteristics of dysphagia and laryngeal movement disorders using standardized assessments to improve diagnosis and care. Participants undergo a structured fiberoptic endoscopic evaluation of swallowing (FEES) with a specific task protocol to observe laryngeal function. When available, laryngeal electromyography (EMG) results are also collected. In addition to these examinations, demographic and disease-specific information is gathered, and participants complete two questionnaires: the Swallowing Disturbance Questionnaire for Parkinson's Disease (SDQ-PD) and the swallowing-specific Quality of Life Questionnaire (SWALQOL). During the study, researchers systematically document laryngeal movement abnormalities and swallowing difficulties in relation to disease subtype and severity. The primary outcomes focus on laryngeal movement disorders and dysphagia measured on the day of assessment. This observational study helps categorize dysphagia patterns across neurodegenerative diseases and correlates findings with clinical subtypes to support earlier and more accurate diagnosis and treatment planning.